The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC).
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst)
 
Naotoshi Sugimoto
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; MSD; Ono Pharmaceutical; Sanofi (Inst); Taiho Pharmaceutical
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Takeshi Kajiwara
Research Funding - Sanofi (Inst)
 
Yoshito Komatsu
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Lilly; Sanofi (Inst)
 
Toru Sasaki
Employment - Sanofi
 
Marielle Chiron
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Samira Ziti-Ljajic
Employment - Sanofi
 
Claire Brillac
Employment - Sanofi
 
Tetsuya Hamaguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - NanoCarrier
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)